Correlation between immune-related adverse events and therapeutic efects of nivolumab in patients with malignant pleural mesothelioma

Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM). However, immunerelated adverse events (irAEs) occur in patients treated with nivolumab. Several studies have reported the correlation between irAEs and therapeutic efects of immune checkpoint inhibitor, but none have reported the correlation in MPM.